Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction Epidermal growth factor receptor (EGFR) mutation is recognized as one of the most important targets in patients with advanced non–small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitor (EGFR-TKI) administration is the standard treatment for NSCLC patients carrying EGFR sensitive mutations. Osimertinib, a third-generation EGFR-TKI, is now used as a first-line strategy for EGFR-positive NSCLC patients [1].
Abstract Anti-estrogen endocrine therapies greatly improve survival of estrogen receptor positive (ER + ) breast cancer. Unfortunately, about 30% of patients do not respond to endocrine therapies initially. We previously showed that deubiquitinase USP35 and ERα act in a positive feedback loop to promote the carcinogenesis of ER+ breast cancer although it is unclear whether USP35 regulates cell death in ER+ breast cancer.
Discussion The main histologic type of bladder cancer is UC. About 3/4 of the tumours are non-muscle invasive UC, and 1/4 of the cases are muscle invasive UC.16 The overall 5-year survival rate for invasive bladder cancer is lower compared with others in the urinary system, with limited response to available treatments such as chemotherapy.
Discussion The main histologic type of bladder cancer is UC. About 3/4 of the tumours are non-muscle invasive UC, and 1/4 of the cases are muscle invasive UC.16 The overall 5-year survival rate for invasive bladder cancer is lower compared with others in the urinary system, with limited response to available treatments such as chemotherapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
